Bioscience

Rondaxe and TD2 form strategic drug development alliance

February 18, 2010

By Flinn Foundation

[Source: Tgen] – TGen Drug Development (TD2) and Rondaxe Enterprises today announced a strategic alliance that will help emerging companies speed new high-quality treatments to cancer patients.

Rondaxe, a drug development consulting company in Syracuse, N.Y., helps emerging pharmaceutical and biotechnology companies navigate through all phases of the drug development and commercialization process. The company specializes in drug chemistry, manufacturing and controls (CMC), quality assurance and control, regulatory affairs and virtual business development.

For more information: Rondaxe and TD2 form strategic drug development alliance